Log in to your Inderes Free account to see all free content on this page.
Cinclus Pharma
19.898
SEK
+0.16 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+0.16%
-23.4%
-34.97%
-
-
-
-
-
-38.97%
cincluspharma.com/sv
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CINPHA
Daily low / high price
19.116 / 20.27
SEK
Market cap
926.01M SEK
Turnover
1.02M SEK
Volume
51K
Financial calendar
Annual report
20.02.2025
Interim report
19.05.2025
General meeting
22.05.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Trill Impact Ventures Pharma 1 | 8.0 % | 8.0 % |
| Fjärde AP-fonden | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: Cinclus Pharma Q3 - Progress in preparations ahead of pivotal study
Interim Report January – September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio